Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.40 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.40 |
| ▸ | RELA | Q04206 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 2/20 | 0.39 |
| ▸ | CA2 | P00918 | 2/20 | 0.39 |
| ▸ | CA7 | P43166 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 3/20 | 0.37 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.37 |
| ▸ | APLNR | P35414 | 1/20 | 0.37 |
| ▸ | CTSK | P43235 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL101218 | 0.86 | DGAT1 (0.46) | DGAT1TDP1NFKB1NFKB2RELA | |
| SCHEMBL3951511 | 0.84 | APLNR (0.41) | DGAT1TDP1NFKB1NFKB2RELA | |
| SCHEMBL1522412 | 0.83 | DGAT1 (0.44) | DGAT1TDP1NFKB1NFKB2RELA | |
| SCHEMBL6272856 | 0.83 | DGAT1 (0.44) | DGAT1TDP1NFKB1NFKB2RELA | |
| Potassium SCHEMBL29554503 | 0.83 | DGAT1 (0.44) | DGAT1TDP1NFKB1NFKB2RELA | |
| SCHEMBL27506147 | 0.82 | MEN1 (0.41) | DGAT1TDP1NFKB1NFKB2RELA | |
| SCHEMBL14949475 | 0.81 | DGAT1 (0.42) | DGAT1TDP1NFKB1NFKB2RELA | |
| SCHEMBL9923753 | 0.80 | GAA (0.40) | DGAT1TDP1NFKB1NFKB2RELA | |
| SCHEMBL10227847 | 0.80 | TDP1 (0.38) | DGAT1TDP1NFKB1NFKB2RELA | |
| SCHEMBL22025144 | 0.80 | TDP1 (0.38) | DGAT1TDP1NFKB1NFKB2RELA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10906919-B2 | Fused pentacyclic imidazole derivatives | UCB Biopharma SRL (BE) | 2021-02-02 | — | — | US | claimed |
| US-6967216-B2 | Amino substituted dibenzothiophene derivatives for the treatment of disorders mediated by NP Y5 receptor | ASTRAZENECA AB (SE) | 2005-11-22 | — | — | US | claimed |
| EP-1140895-B1 | THIOPYRAN COMPOUNDS AS INHIBITORS OF MMP | FUJISAWA PHARMACEUTICAL CO (JP) | 2004-03-24 | — | — | EP | claimed |
| US-20030225097-A1 | Amino substituted dibenzothiophene derivatives for the treatment of disorders mediated by np y5 receptor | ASTRAZENECA AB (SE) | 2003-12-04 | — | — | US | claimed |
| WO-2003018019-A2 | NEW USE OF CYCLIC COMPOUNDS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-03-06 | — | — | WO | claimed |
| EP-1278739-A1 | AMINO SUBSTITUTED DIBENZOTHIOPHENE DERIVATIVES FOR THE TREATMENT OF DISORDERS MEDIATED BY THE NP Y5 RECEPTOR | AstraZeneca AB (SE) | 2003-01-29 | — | — | EP | claimed |
| US-6376548-B1 | FUNGICIDES; HERBICIDES; INSECTICIDES | ROHM AND HAAS COMPANY | 2002-04-23 | — | — | US | claimed |
| WO-2001085714-A1 | AMINO SUBSTITUTED DIBENZOTHIOPHENE DERIVATIVES FOR THE TREATMENT OF DISORDERS MEDIATED BY THE NP Y5 RECEPTOR | ASTRAZENECA AB (SE) | 2001-11-15 | — | — | WO | claimed |
| US-11912721-B2 | Fused pentacyclic imidazole derivatives | UCB Biopharma SRL (BE) | 2024-02-27 | — | — | US | disclosed |
| CN-114728976-A | HYDRO-1H-PYRROLO [1,2-A ] PYRAZINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISORDERS | 豪夫迈·罗氏有限公司 | 2022-07-08 | — | — | CN | disclosed |
| EP-3436456-B1 | FUSED HEXACYCLIC IMIDAZOLE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB Biopharma SRL (BE) | 2021-11-17 | — | — | EP | disclosed |
| EP-3436460-B1 | FUSED PENTACYCLIC IMIDAZOLE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB Biopharma SRL (BE) | 2021-08-18 | — | — | EP | disclosed |
| EP-3201196-B1 | FUSED PENTACYCLIC IMIDAZOLE DERIVATIVES | UCB Biopharma SRL (BE) | 2021-07-28 | — | — | EP | disclosed |
| US-20210155637-A1 | Fused Pentacyclic Imidazole Derivatives | SANOFI (FR) | 2021-05-27 | — | — | US | disclosed |
| EP-1140895-B1 | THIOPYRAN COMPOUNDS AS INHIBITORS OF MMP | FUJISAWA PHARMACEUTICAL CO (JP) | 2004-03-24 | — | — | EP | disclosed |
| US-20030225097-A1 | Amino substituted dibenzothiophene derivatives for the treatment of disorders mediated by np y5 receptor | ASTRAZENECA AB (SE) | 2003-12-04 | — | — | US | disclosed |
| EP-1278739-A1 | AMINO SUBSTITUTED DIBENZOTHIOPHENE DERIVATIVES FOR THE TREATMENT OF DISORDERS MEDIATED BY THE NP Y5 RECEPTOR | AstraZeneca AB (SE) | 2003-01-29 | — | — | EP | disclosed |
| US-6376548-B1 | FUNGICIDES; HERBICIDES; INSECTICIDES | ROHM AND HAAS COMPANY | 2002-04-23 | — | — | US | disclosed |
| WO-2001085714-A1 | AMINO SUBSTITUTED DIBENZOTHIOPHENE DERIVATIVES FOR THE TREATMENT OF DISORDERS MEDIATED BY THE NP Y5 RECEPTOR | ASTRAZENECA AB (SE) | 2001-11-15 | — | — | WO | disclosed |
| WO-2001056358-A2 | ENHANCED PROPERTIED PESTICIDES | ROHM AND HAAS COMPANY (US) | 2001-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10906919-B2 | Fused pentacyclic imidazole derivatives | TNF, NFKBIA, TNFRSF1A | DGAT1 4135/4885TDP1 545/4885NFKB1 14/4885 |
| US-20210155637-A1 | Fused Pentacyclic Imidazole Derivatives | TNF, NFKBIA, TNFRSF1A | DGAT1 4135/4885TDP1 545/4885NFKB1 14/4885 |
| US-11912721-B2 | Fused pentacyclic imidazole derivatives | TNF, NFKBIA, TNFRSF1A | DGAT1 4135/4885TDP1 545/4885NFKB1 14/4885 |
| US-20030225097-A1 | Amino substituted dibenzothiophene derivatives for the treatment of disorders mediated by np y5 receptor | NPY5R, NPY1R, NPY2R | DGAT1 2988/4885TDP1 1409/4885NFKB1 1290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.